Peripartum Cardiomyopathy: Do Exosomes Play a Role?

  • Huanyu Gu
  • Qiying Dai
  • Zhuyuan Liu
  • Hongbao Wang
  • Jianhua YaoEmail author
  • Lei ZhouEmail author
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 998)


Peripartum cardiomyopathy (PPCM) refers to irreversible cardiomyocyte damage that occurs during the last month of pregnancy, or within 5 months after giving birth. It is characterized by systolic heart failure. This life-threatening condition is relatively uncommon, but the incidence has been climbing up. Because of its high mortality, it is crucial for physicians to have high suspicious for the disease. Studies have been done to search into specific lab test and treatment for PPCM. Therapies like anti-viral, anti-inflammatory and immunosuppression regimen have been explored. New regimen like exosomes has also been explored and revealed promising effects.


Peripartum cardiomyopathy Exosome 



This work was supported by the grants from National Natural Science Foundation of China (81370280 and 81570332), the grant from Yangpu Commission of Science and Technology Commission, and Yangpu Commission of Health and Family Planning (YP15M07), and the “Chenguang Program” supported by Yangpu Hospital, Tongji University School of Medicine (Ye1201409).

Competing Financial Interests The authors declare no competing financial interests.


  1. 1.
    Demakis JG, Rahimtoola SH, Sutton GC, Meadows WR, Szanto PB, Tobin JR, Gunnar RM (1971) Natural course of peripartum cardiomyopathy. Circulation 44(6):1053–1061CrossRefPubMedGoogle Scholar
  2. 2.
    Hibbard JU, Lindheimer M, Lang RM (1999) A modified definition for peripartum cardiomyopathy and prognosis based on echocardiography. Obstet Gynecol 94(2):311–316PubMedGoogle Scholar
  3. 3.
    Deneux-Tharaux C, Berg C, Bouvier-Colle MH, Gissler M, Harper M, Nannini A, Alexander S, Wildman K, Breart G, Buekens P (2005) Underreporting of pregnancy-related mortality in the United States and Europe. Obstet Gynecol 106(4):684–692CrossRefPubMedGoogle Scholar
  4. 4.
    Brar SS, Khan SS, Sandhu GK, Jorgensen MB, Parikh N, Hsu JW, Shen AY (2007) Incidence, mortality, and racial differences in peripartum cardiomyopathy. Am J Cardiol 100(2):302–304CrossRefPubMedGoogle Scholar
  5. 5.
    Desai D, Moodley J, Naidoo D (1995) Peripartum cardiomyopathy: experiences at King Edward VIII Hospital, Durban, South Africa and a review of the literature. Trop Dr 25(3):118–123Google Scholar
  6. 6.
    Elkayam U (2011) Clinical characteristics of peripartum cardiomyopathy in the United States: diagnosis, prognosis, and management. J Am Coll Cardiol 58(7):659–670CrossRefPubMedGoogle Scholar
  7. 7.
    Ferriere M, Sacrez A, Bouhour JB, Cassagnes J, Geslin P, Dubourg O, Komajda M, Degeorges M (1990) Cardiomyopathy in the peripartum period: current aspects. A multicenter study. 11 cases. Arch Mal Coeur Vaiss 83(10):1563–1569PubMedGoogle Scholar
  8. 8.
    Gentry MB, Dias JK, Luis A, Patel R, Thornton J, Reed GL (2010) African-American women have a higher risk for developing peripartum cardiomyopathy. J am Coll Cardiol 55(7):654–659CrossRefPubMedGoogle Scholar
  9. 9.
    Sliwa K, Skudicky D, Candy G, Bergemann A, Hopley M, Sareli P (2002) The addition of pentoxifylline to conventional therapy improves outcome in patients with peripartum cardiomyopathy. Eur J Heart Fail 4(3):305–309CrossRefPubMedGoogle Scholar
  10. 10.
    Pearson GD, Veille JC, Rahimtoola S, Hsia J, Oakley CM, Hosenpud JD, Ansari A, Baughman KL (2000) Peripartum cardiomyopathy: National Heart, Lung, and Blood Institute and Office of Rare Diseases (National Institutes of Health) workshop recommendations and review. J Am Med Assoc 283(9):1183–1188CrossRefGoogle Scholar
  11. 11.
    Sliwa K, Skudicky D, Bergemann A, Candy G, Puren A, Sareli P (2000) Peripartum cardiomyopathy: analysis of clinical outcome, left ventricular function, plasma levels of cytokines and Fas/APO-1. J Am Coll Cardiol 35(3):701–705CrossRefPubMedGoogle Scholar
  12. 12.
    Sliwa K, Forster O, Libhaber E, Fett JD, Sundstrom JB, Hilfiker-Kleiner D, Ansari AA (2006) Peripartum cardiomyopathy: inflammatory markers as predictors of outcome in 100 prospectively studied patients. Eur Heart J 27(4):441–446CrossRefPubMedGoogle Scholar
  13. 13.
    Chapa JB, Heiberger HB, Weinert L, Decara J, Lang RM, Hibbard JU (2005) Prognostic value of echocardiography in peripartum cardiomyopathy. Obstet Gynecol 105(6):1303–1308CrossRefPubMedGoogle Scholar
  14. 14.
    Ntusi NB, Mayosi BM (2009) Aetiology and risk factors of peripartum cardiomyopathy: a systematic review. Int J Cardiol 131(2):168–179CrossRefPubMedGoogle Scholar
  15. 15.
    Sanderson JE, Olsen EG, Gatei D (1986) Peripartum heart disease: an endomyocardial biopsy study. Br Heart J 56(3):285–291CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Sliwa K, Forster O, Tibazarwa K, Libhaber E, Becker A, Yip A, Hilfiker-Kleiner D (2011) Long-term outcome of peripartum cardiomyopathy in a population with high seropositivity for human immunodeficiency virus. Int J Cardiol 147(2):202–208CrossRefPubMedGoogle Scholar
  17. 17.
    Lyden DC, Huber SA (1984) Aggravation of coxsackievirus, group B, type 3-induced myocarditis and increase in cellular immunity to myocyte antigens in pregnant Balb/c mice and animals treated with progesterone. Cell Immunol 87(2):462–472CrossRefPubMedGoogle Scholar
  18. 18.
    Ansari AA, Fett JD, Carraway RE, Mayne AE, Onlamoon N, Sundstrom JB (2002) Autoimmune mechanisms as the basis for human peripartum cardiomyopathy. Clin Rev Allergy Immunol 23(3):301–324CrossRefPubMedGoogle Scholar
  19. 19.
    Hayakawa Y, Chandra M, Miao W, Shirani J, Brown JH, Dorn GW II, Armstrong RC, Kitsis RN (2003) Inhibition of cardiac myocyte apoptosis improves cardiac function and abolishes mortality in the peripartum cardiomyopathy of Galpha(q) transgenic mice. Circulation 108(24):3036–3041CrossRefPubMedGoogle Scholar
  20. 20.
    Selle T, Renger I, Labidi S, Bultmann I, Hilfiker-Kleiner D (2009) Reviewing peripartum cardiomyopathy: current state of knowledge. Futur Cardiol 5(2):175–189CrossRefGoogle Scholar
  21. 21.
    Bültmann BD, Klingel K, Näbauer M, Wallwiener D, Kandolf R (2005) High prevalence of viral genomes and inflammation in peripartum cardiomyopathy. Am J Obstet Gynecol 193(2):363–365CrossRefPubMedGoogle Scholar
  22. 22.
    Kuhl U, Pauschinger M, Seeberg B, Lassner D, Noutsias M, Poller W, Schultheiss HP (2005) Viral persistence in the myocardium is associated with progressive cardiac dysfunction. Circulation 112(13):1965–1970CrossRefPubMedGoogle Scholar
  23. 23.
    Hilfiker-Kleiner D, Kaminski K, Podewski E, Bonda T, Schaefer A, Sliwa K, Forster O, Quint A, Landmesser U, Doerries C, Luchtefeld M, Poli V, Schneider MD, Balligand JL, Desjardins F, Ansari A, Struman I, Nguyen NQ, Zschemisch NH, Klein G, Heusch G, Schulz R, Hilfiker A, Drexler H (2007) A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy. Cell 128(3):589–600CrossRefPubMedGoogle Scholar
  24. 24.
    Patten IS, Rana S, Shahul S, Rowe GC, Jang C, Liu L, Hacker MR, Rhee JS, Mitchell J, Mahmood F, Hess P, Farrell C, Koulisis N, Khankin EV, Burke SD, Tudorache I, Bauersachs J, del Monte F, Hilfiker-Kleiner D, Karumanchi SA, Arany Z (2012) Cardiac angiogenic imbalance leads to peripartum cardiomyopathy. Nature 485(7398):333–338CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Fett JD, Carraway RD, Dowell DL, King ME, Pierre R (2002) Peripartum cardiomyopathy in the Hospital Albert Schweitzer District of Haiti. Am J Obstet Gynecol 186(5):1005–1010CrossRefPubMedGoogle Scholar
  26. 26.
    Keyser EA, Reed BG, Gonzalez-Brown V, Fausett B, Staat BC, Leath CA (2012) Peripartum cardiomyopathy and acute fatty liver of pregnancy: one patient with two zebras. Mil Med 177(4):470–473CrossRefPubMedGoogle Scholar
  27. 27.
    Shah T, Ather S, Bavishi C, Bambhroliya A, Ma T, Bozkurt B (2013) Peripartum cardiomyopathy: a contemporary review. Methodist Debakey Cardiovasc J 9(1):38–43CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Diao M, Diop IB, Kane A, Camara S, Kane A, Sarr M, Ba SA, Diouf SM (2004) Electrocardiographic recording of long duration (Holter) of 24 hours during idiopathic cardiomyopathy of the peripartum. Arch Mal Coeur Vaiss 97(1):25–30PubMedGoogle Scholar
  29. 29.
    Meyer GP, Labidi S, Podewski E, Sliwa K, Drexler H, Hilfiker-Kleiner D (2010) Bromocriptine treatment associated with recovery from peripartum cardiomyopathy in siblings: two case reports. J Med Case Rep 4(1):80–84CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Helms AK, Kittner SJ (2005) Pregnancy and stroke. CNS Spectr 10(7):580–587CrossRefPubMedGoogle Scholar
  31. 31.
    Mayosi BM (2007) Contemporary trends in the epidemiology and management of cardiomyopathy and pericarditis in sub-Saharan Africa. Heart 93(10):1176–1183CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Napporn A, Kane A, Damorou J, Dia A, Diop I, Sarr M, Ba S, Diouf S (2000) Intraventricular thrombosis complicating peri-partum idiopathic myocardiopathy. Annales de Cardiologie et D’angeiologie 49(5):309–314PubMedGoogle Scholar
  33. 33.
    Bhakta P, Biswas BK, Banerjee B (2007) Peripartum cardiomyopathy: review of the literature. Yonsei Med J 48(5):731–747CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Forster O, Hilfiker-Kleiner D, Ansari AA, Sundstrom JB, Libhaber E, Tshani W, Becker A, Yip A, Klein G, Sliwa K (2008) Reversal of IFN-gamma, oxLDL and prolactin serum levels correlate with clinical improvement in patients with peripartum cardiomyopathy. Eur J Heart Fail 10(9):861–868CrossRefPubMedGoogle Scholar
  35. 35.
    Halkein J, Tabruyn SP, Ricke-Hoch M, Haghikia A, Nguyen NQ, Scherr M, Castermans K, Malvaux L, Lambert V, Thiry M, Sliwa K, Noel A, Martial JA, Hilfiker-Kleiner D, Struman I (2013) MicroRNA-146a is a therapeutic target and biomarker for peripartum cardiomyopathy. J Clin Investig 123(5):2143–2154CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Hu CL, Li YB, Zou YG, Zhang JM, Chen JB, Liu J, Tang YH, Tang QZ, Huang CX (2007) Troponin T measurement can predict persistent left ventricular dysfunction in peripartum cardiomyopathy. Heart 93(4):488–490CrossRefPubMedGoogle Scholar
  37. 37.
    Holzmann M, Nicko A, Kuhl U, Noutsias M, Poller W, Hoffmann W, Morguet A, Witzenbichler B, Tschope C, Schultheiss HP, Pauschinger M (2008) Complication rate of right ventricular endomyocardial biopsy via the femoral approach: a retrospective and prospective study analyzing 3048 diagnostic procedures over an 11-year period. Circulation 118(17):1722–1728CrossRefPubMedGoogle Scholar
  38. 38.
    Bhattacharyya A, Basra SS, Sen P, Kar B (2012) Peripartum cardiomyopathy: a review. Tex Heart Inst J 39(1):8–16PubMedPubMedCentralGoogle Scholar
  39. 39.
    Amos AM, Jaber WA, Russell SD (2006) Improved outcomes in peripartum cardiomyopathy with contemporary. Am Heart J 152(3):509–513CrossRefPubMedGoogle Scholar
  40. 40.
    Witlin AG, Mabie WC, Sibai BM (1997) Peripartum cardiomyopathy: an ominous diagnosis. Am J Obstet Gynecol 176(1):182–188CrossRefPubMedGoogle Scholar
  41. 41.
    Witlin AG, Mabie WC, Sibai BM (1997) Peripartum cardiomyopathy: a longitudinal echocardiographic study. Am J Obstet Gynecol 177(5):1129–1132CrossRefPubMedGoogle Scholar
  42. 42.
    Murali S, Baldisseri MR (2005) Peripartum cardiomyopathy. Crit Care Med 33(10):340–346CrossRefGoogle Scholar
  43. 43.
    Heart Failure Society of A, Lindenfeld J, Albert NM, Boehmer JP, Collins SP, Ezekowitz JA, Givertz MM, Katz SD, Klapholz M, Moser DK, Rogers JG, Starling RC, Stevenson WG, Tang WH, Teerlink JR, Walsh MN (2010) HFSA 2010 comprehensive heart failure practice guideline. J Card Fail 16(6):1–194Google Scholar
  44. 44.
    Adams KF Jr, Patterson JH, Gattis WA, O’Connor CM, Lee CR, Schwartz TA, Gheorghiade M (2005) Relationship of serum digoxin concentration to mortality and morbidity in women in the digitalis investigation group trial: a retrospective analysis. J Am Coll Cardiol 46(3):497–504CrossRefPubMedGoogle Scholar
  45. 45.
    Briggs GG, Ambrose PJ, Nageotte MP, Padilla G (2008) High-dose carisoprodol during pregnancy and lactation. Ann Pharmacother 42(6):898–901CrossRefPubMedGoogle Scholar
  46. 46.
    Shotan A, Widerhorn J, Hurst A, Elkayam U (1994) Risks of angiotensin-converting enzyme inhibition during pregnancy: experimental and clinical evidence, potential mechanisms, and recommendations for use. Am J Med 96(5):451–456CrossRefPubMedGoogle Scholar
  47. 47.
    Hurst A, Hoffman K, Frishman W, Elkayam U (1998) The use of beta adrenergic blocking agents in pregnancy and lactation. Wiley Liss 3(3):357–372Google Scholar
  48. 48.
    American Academy of Pediatrics Committee on D (2001) Transfer of drugs and other chemicals into human milk. Pediatrics 108(3):776–789CrossRefGoogle Scholar
  49. 49.
    Shimamoto T, Marui A, Oda M, Tomita S, Nakajima H, Takeuchi T, Komeda M (2008) A case of peripartum cardiomyopathy with recurrent left ventricular apical thrombus. Circ J 72(5):853–854CrossRefPubMedGoogle Scholar
  50. 50.
    Briggs GG, Freeman RK, Yaffe SJ (2012) Drugs in pregnancy and lactation: a reference guide to fetal and neonatal risk. Lippincott Williams & Wilkins 10:1–1600Google Scholar
  51. 51.
    Turkalj I, Braun P, Krupp P (1982) Surveillance of bromocriptine in pregnancy. J Am Med Assoc 247(11):1589–1591CrossRefGoogle Scholar
  52. 52.
    Barile L, Moccetti T, Marban E, Vassalli G (2016) Roles of exosomes in cardioprotection. Eur Heart J 7(21):304–312CrossRefGoogle Scholar
  53. 53.
    Hajivalili M, Pourgholi F, Majidi J, Aghebati-Maleki L, Movassaghpour AA, Samadi Kafil H, Mirshafiey A, Yousefi M (2016) G2013 modulates TLR4 signaling pathway in IRAK-1 and TARF-6 dependent and miR-146a independent manner. Cell Mol Biol 62(4):1–5PubMedGoogle Scholar
  54. 54.
    Lorello G, Cubillos J, McDonald M, Balki M (2014) Peripartum cardiomyopathy: postpartum decompensation and use of non-invasive cardiac output monitoring. Int J Obstet Anesth 23(1):66–70CrossRefPubMedGoogle Scholar
  55. 55.
    Rose EA, Moskowitz AJ, Packer M, Sollano JA, Williams DL, Tierney AR, Heitjan DF, Meier P, Ascheim DD, Levitan RG, Weinberg AD, Stevenson LW, Shapiro PA, Lazar RM, Watson JT, Goldstein DJ, Gelijns AC (1999) The rematch trial: rationale, design, and end points. Randomized evaluation of mechanical assistance for the treatment of congestive heart failure. Ann Thorac Surg 67(3):723–730CrossRefPubMedGoogle Scholar
  56. 56.
    Jessup M, Brozena S (2003) Heart failure. N Engl J Med 348(20):2007–2018CrossRefPubMedGoogle Scholar
  57. 57.
    Duran N, Gunes H, Duran I, Biteker M, Ozkan M (2008) Predictors of prognosis in patients with peripartum cardiomyopathy. Int J Obstet Gynaecol 101(2):137–140CrossRefGoogle Scholar
  58. 58.
    Modi KA, Illum S, Jariatul K, Caldito G, Reddy PC (2009) Poor outcome of indigent patients with peripartum cardiomyopathy in the United States. Am J Obstet Gynecol 201(2):171–175CrossRefPubMedGoogle Scholar
  59. 59.
    Biteker M (2012) Peripartum cardiomyopathy in Turkey. Int J Cardiol 158(3):60–61CrossRefGoogle Scholar
  60. 60.
    Blauwet LA, Sliwa K (2011) Peripartum cardiomyopathy. Obstet Med 4(2):44–52CrossRefPubMedPubMedCentralGoogle Scholar
  61. 61.
    Gao M, Wang X, Zhang X, Ha T, Ma H, Liu L, Kalbfleisch JH, Gao X, Kao RL, Williams DL, Li C (2015) Attenuation of cardiac dysfunction in polymicrobial sepsis by microRNA-146a is mediated via targeting of IRAK1 and TRAF6 expression. J Immunol 195(2):672–682CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2017

Authors and Affiliations

  1. 1.Department of CardiologyFirst Affiliated Hospital of Nanjing Medical UniversityNanjingChina
  2. 2.Metrowest Medical CenterFraminghamUSA
  3. 3.Department of CardiologyYangpu Hospital, Tongji University School of MedicineShanghaiChina

Personalised recommendations